2009
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window
Saver J, Gornbein J, Grotta J, Liebeskind D, Lutsep H, Schwamm L, Scott P, Starkman S. Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window. Stroke 2009, 40: 2433-2437. PMID: 19498197, PMCID: PMC2724988, DOI: 10.1161/strokeaha.108.543561.Peer-Reviewed Original ResearchConceptsTissue plasminogen activatorRankin ScaleIntravenous tissue plasminogen activator therapyIntravenous tissue plasminogen activatorTissue plasminogen activator therapyPlasminogen activatorAcute cerebral ischemiaModified Rankin ScalePlasminogen activator therapyResults of therapyEffect sizeCerebral ischemiaPoststroke disabilityAdditional patientsActivator therapyWorse outcomesGlobal disabilityTreatment decisionsBetter outcomesClinical practicePatientsNNTBLikelihood of helpEffect size estimatesTable analysis
1998
Effects of Induced Hypertension on Transcranial Doppler Ultrasound Velocities in Patients After Subarachnoid Hemorrhage
Manno E, Gress D, Schwamm L, Diringer M, Ogilvy C. Effects of Induced Hypertension on Transcranial Doppler Ultrasound Velocities in Patients After Subarachnoid Hemorrhage. Stroke 1998, 29: 422-428. PMID: 9472884, DOI: 10.1161/01.str.29.2.422.Peer-Reviewed Original ResearchConceptsMiddle cerebral arteryInduced hypertensionTCD velocitiesSubarachnoid hemorrhageTranscranial Doppler ultrasoundIntact autoregulationArterial pressureCerebral vasospasmCerebral arteryCerebral autoregulationTranscranial Doppler ultrasound velocitiesCerebral blood flow velocityContinuous TCD monitoringMean arterial pressureBlood flow velocityLevel of autoregulationDoppler ultrasound velocitiesAdditional patientsClinical evidenceClinical differencesTCD monitoringHypertensionDoppler ultrasoundHemorrhagePatients